Randomized trial evaluates adjuvant therapy with a personalized neoantigen vaccine in high-risk esophageal carcinoma, suggesting enhanced survival benefits.
Key Points
The study aims to assess the safety and efficacy of a personalized neoantigen peptide vaccine as adjuvant therapy in high-risk postoperative esophageal carcinoma patients.
Single-arm clinical trial (NCT05307835)
Enrolled stage IIA-IIIB EC patients with non-pCR and designed personalized peptides
Administered vaccine subcutaneously with GM-CSF on a multi-dose schedule.
1-year recurrence-free survival (RFS) rate was 91.3%; 3-year RFS rate was 78.5%;
1-year overall survival (OS) rate was 100%; 3-year OS rate was 83.1%;
100% of patients showed neoantigen-specific T-cell responses, with durable T-cell activation.